Stocks on Location Levantine Hill Estate featuring SPL, ACQ, AXL & AQX

We're proud to share that The Capital Network, in partnership with leading executive search and board advisory firm Foley Durham, has just hosted the fourth edition of Stocks on Location.

This exclusive series of events is designed to bring investors and executives together in some of Australia’s most iconic settings.

Each curated experience connects ASX-listed companies shaping Australia’s next chapter of growth with founder-led business owners, institutional investors, private equity, family offices, CEOs, directors, and senior executives.

Our most recent instalment, Stocks on Location: On Wineries, took us to Victoria’s stunning Yarra Valley.

Held at the immaculate Levantine Hill Estate, the private luncheon welcomed more than 100 sophisticated investors who enjoyed insights from executives representing four emerging and fast-growing ASX-listed businesses.

We now turn our attention to the next Stocks On Location: On Track gathering, taking place at Royal Randwick in Sydney on Wednesday, 11 March 2026.

This event will showcase several ASX-listed presenters over a premium two-course luncheon with accompanying beverages.

Readers interested in attending future marquee events are invited to join the Stocks On Location membership program.

Annual membership provides access to tickets for any of our signature events, hosted at prestigious venues including racetracks, wineries and sporting arenas.

Starpharma gains global traction for next gen medical products

Starpharma Holdings (ASX:SPL, OTCQX: SPHRY) is a global biotechnology business developing next-generation pharmaceutical and medical products using its proprietary dendrimer technology.

In essence, dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties - including size, structure, and water solubility - make them highly valuable for medical applications.

Starpharma’s mission is to leverage this technology to improve health outcomes and the quality of life for patients with serious diseases, including cancer.

The company recently secured two significant agreements that provide strong external validation of its dendrimer-enhanced product (DEP) platform and scientific capabilities.

Firstly, it entered a deal with Genentech - a member of the Roche Group - to develop dendrimer-drug conjugates incorporating Genentech medicines directed to selected cancer targets.

This deal included an upfront payment of US$5.5 million, potential future milestone payments of up to US$564 million, and tiered royalties on global net sales.

Secondly, Starpharma also entered a research and option agreement with Radiopharm Theranostics to develop and manufacture a dendrimer-drug conjugate containing a radiopharmaceutical molecule.

The arrangement grants Radiopharm an exclusive option to license the asset.

Under this agreement, Starpharma is eligible to receive a A$2 million upfront payment, up to A$89 million in success-based milestones, and royalties on future net sales.

This collaboration marks Starpharma’s first partnership in radiopharmaceuticals, expanding the reach of its DEP platform into an emerging field.

Acorn drives growth with proven microcap investment framework 

Acorn Capital Investment Fund (ASX:ACQ) is a listed investment company managed by Acorn Capital.

It provides investors with access to a diversified portfolio of emerging Australian microcap businesses - both public and private.

In other words, ACQ offers exposure to the innovation and growth potential of emergent Australian companies from a broad range of sectors such as biotech, fintech, resources, and manufacturing.

The fund typically holds between 60 and 80 stocks and seeks to deliver long-term capital growth through rigorous bottom-up research into smaller, often under-followed companies that could benefit from structural inefficiencies within their markets.

A disciplined, systematic investment approach underpins Acorn Capital’s process.

In essence, the same investment strategy deployed by Acorn Capital for ACQ has already been implemented for its institutional clients since February 2009.

This strategy enables Acorn Capital to confidently navigate the dynamics of the microcap sector, which behaves differently from the broader market due to its composition and the characteristics of the underlying companies.

Management defines ‘microcaps’ as companies with a market capitalisation below that of the 250th largest business on the ASX.

At present, this corresponds to companies with market caps of less than $1.2 billion.

Axel emerges as a globally significant gallium and rare earths player

Axel REE (ASX:AXL, FSE:HN8) is critical minerals exploration company focused on advancing its rare earths and gallium projects in Brazil.

Since listing on the ASX in July last year, Axel has transformed from an early-stage explorer into the owner of two substantial JORC-compliant resources at its flagship Caladão project.

In August, the company unveiled a maiden gallium resource estimate for the Area A prospect, consisting of 100 million tonnes at 42 parts per million (ppm) gallium.

This equates to 4,200 tonnes of contained gallium.

Management believes that Caladão positions Axel amongst the very few companies globally with a stand-alone gallium resource, rather than relying on a low-value by-product from environmentally intensive alumina refining.

In October, Axel upped the ante by adding a maiden rare earth resource estimate at Area A, consisting of 233 million tonnes at 2,143 ppm total rare earth oxide (TREO).

Notably, about 22 per cent of the resource comprises higher-value magnet rare earth oxides - neodymium, praseodymium, dysprosium, and terbium.

These elements are essential for high-performance permanent magnets used in electric vehicles (EV), wind turbines, and advanced defence and industrial technologies.

Together, these milestones reinforce management’s view that Caladão is emerging as a strategically significant critical minerals asset on the global stage.

Alice Queen unveils high-grade gold potential in Fiji

Alice Queen (ASX:AQX) is a mineral explorer with a portfolio of gold and copper-gold projects in Fiji, the Northern Molong Volcanic Belt in New South Wales, and on Horn Island in the Torres Strait.

In recent months, the company has focused its exploration activities on its wholly owned Viani gold project in Fiji.

Here, previous sampling, trenching, and limited historical drilling at the Dakuniba prospect revealed epithermal gold mineralisation over a strike length stretching for more than three kilometres.

Surface exploration also outlined a 5km by 1.5km surface gold-in-soil geochemical anomaly. Management believes this mineralised footprint is comparable to other economically productive epithermal gold deposits around the world.

And Alice Queen recently wrapped up its maiden exploration and diamond drilling campaign at Viani.

Amongst others, the four hole drilling program at Dakuniba delivered a standout hit of 4.14 metres grading 6.13 grams per tonne gold form 196m.

Notably, the intercept confirmed the continuity of a rich gold zone from surface to a depth of 175m. It also returned two discrete high-grade intervals of 0.58m at 26.4 g/t gold and 0.8m at 11.4 g/t gold.

Additional surface sampling over a 5km strike length at Dakuniba also highlighted further high-grade potential.

For instance, rock sampling from an epithermal quartz vein located 2.3km to the east of recent drilling returned up to 9.23 g/t gold. Trenches 500 metres east from the drilling area also delivered encouraging results, including 3m at 14.3 g/t gold.

Alice Queen now plans to progress Viani with a program involving geological mapping, ground magnetics, CSAMT surveying, and continued surface geochemical sampling.